<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
</head>
<body><p><span ><strong><u>ANAEMIA IN CHRONIC KIDNEY DISEASE</u></strong></span></p><p style="margin-left:0cm;text-align:justify;"><span >Anaemia develops early in the course of Chronic Kidney Disease (CKD) and is nearly universal in patients with CKD stage 5 (End-stage kidney disease).The prevalence of anaemia at higher levels of glomerular filtration rate (GFR) (i.e. CKD stage 1-2) is relatively low in individuals from the general population. Anaemia of CKD is primarily caused by deficiency of erythropoietin. The kidneys are the major source of erythropoietin and, as renal function declines, production of erythropoietin declines proportionately.</span></p><p style="margin-left:0cm;text-align:justify;"><span >Though erythropoietin deficiency is common among patients with anaemia in CKD, other potential causes and contributing disorders should be identified or excluded if initial evaluation yields evidence for disorders other than iron deficiency or erythropoietin deficiency. Correction of anaemia in CKD patients improves survival and quality of life.</span></p><h3 style="margin-left:0cm;">CAUSES</h3><ul><li>Deficiency of erythropoietin</li><li>Red cell destruction from microvascular disease from diabetes or hypertension</li><li>Increased gastrointestinal bleeding</li><li>Increased oxidative stress leading to shortened red cell survival</li></ul><h3 style="margin-left:0cm;">SYMPTOMS</h3><ul><li><span >(See section on 'Anaemia')</span></li></ul><p style="margin-left:0cm;"><span ><strong>SIGN</strong></span></p><ul><li><span >(See section on 'Anaemia')</span></li></ul><h3 style="margin-left:0cm;">INVESTIGATIONS</h3><ul><li>FBC</li><li>Reticulocyte count</li><li>Transferrin saturation</li><li>Serum ferritin</li><li>Stool occult blood</li></ul><h3 style="margin-left:0cm;">TREATMENT</h3><p><strong>Treatment objectives</strong></p><ul><li>To achieve and maintain a target-range Hb level of 11-12 g/dL</li></ul><h3 style="margin-left:0cm;">Non-pharmacological treatment</h3><ul><li><span >(See section on 'Anaemia')</span></li></ul><h3 style="margin-left:0cm;">Pharmacological treatment</h3><ol><li><span ><strong>CKD Stages 1-2</strong></span></li></ol><p style="margin-left:0cm;"><span >1<sup>st</sup> Line Treatment Evidence Rating: [A]</span></p><ul><li>Ferrous sulphate, oral, 325 mg 8 hourly for 4 weeks</li></ul><ol><li><span >CKD Stages 3-4</span></li></ol><p style="margin-left:0cm;"><span ><strong>Iron replacement</strong>: Target Hb should be 11-12 g/dL</span></p><ul><li>Ferrous sulphate, oral, 325 mg 8 hourly</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Ferrous gluconate, oral, 300 mg 8-12 hourly. Evaluate after 4-6 weeks</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Iron sucrose, IV, consult specialist</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Ferric sodium gluconate complex, consult specialist</li></ul><h3 style="margin-left:0cm;">And</h3><ul><li>Epoetin beta, SC, consult specialist</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Methoxy polyethylene glycol epoetin beta (pegylated form of Epo), SC, consult specialist</li></ul><h3 style="margin-left:0cm;">Or</h3><p style="margin-left:0cm;">Darbepoetin alfa, SC, consult specialist</p><p style="margin-left:0cm;"> </p><h3 style="margin-left:0cm;">REFERRAL CRITERIA</h3><p style="margin-left:0cm;"><span >Refer all (adults and children) patients with CKD and anaemia to a specialist or nephrologist.</span></p><p style="margin-left:0cm;"> </p><p> </p>
</body>
</html>
